Hummsa Biotech is pioneering next-generation GLP-1 therapeutics focused on optimizing metabolic health to extend healthspan and delay age-related diseases
Hummsa Biotech is pioneering next-generation GLP-1 therapeutics focused on optimizing metabolic health to extend healthspan and delay age-related diseases. Their lead candidate, an oral small molecule GLP-1 receptor agonist, aims to regenerate insulin-producing beta cells and prevent chronic diseases.